Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: Marker of risk or cardioprotection in the real world?

Oncologist

Volumn 17, Issue 7, 2012, Pages 917-924

  Oliva, Stefano ^a   Cioffi, Giovanni ^b   Frattini, Silvia ^c   Simoncini, Edda Lucia ^c   Faggiano, Pompilio ^c   Boccardi, Lidia ^d   Pulignano, Giovanni ^d   Fioretti, Agnese Maria ^d   Giotta, Francesco ^a   Lestuzzi, Chiara ^e   Maurea, Nicola ^f   Sabatini, Silvia ^g   Tarantini, Luigi ^h  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Villa Bianca Hospital   (Italy)

^c Spedali Riuniti   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g S MARIA HOSPITAL   (Italy)

^h SAN MARTINO HOSPITAL   (Italy)

Author keywords

blockers; Angiotensin converting enzyme inhibitors; Breast cancer; Cardiotoxicity; Trastuzumab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIRUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME;

EID: 84864059254     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0445     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
2. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31:459-467.
3. 111Indium trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanism of trastuzumab-related cardiotoxicity Eur J Cancer 2007;43:2046-2051.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
5. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465.
6. Pugatsch T, Abedat S, Lotan C et al. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 2006;8:R35.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
8. Tan-Chiu E, Yothers G, Romond EH et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
9. Perez EA, Romond EH, Suman VJ et al. Updated results of the combined analysis of NCCTG N9831and NSABP B-31adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc ASCO 2007;25:512.
10. Smith I, Procter M, Gelber RD et al. 2-year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
11. Perez EA, Suman VJ, Davidson NE. Exploratory Analysis From NCCTGN9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Proc SABCS 2005;2038.
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
13. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
14. Dahabreh IJ, Linardou H, Siannis F et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. The Oncologist 2008;13:620-630.
15. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859-3865.
16. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808-3815.
17. Guglin M, Hartlage G, Reynolds C et al. Trastuzumab-induced cardiomyopathy: Not as benign as it looks? A retrospective study. J Card Fail 2009;15:651-657.
18. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
19. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262.
20. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28:3910-3916.
21. Graham I, Atar D, Borch-Johnsen K et al. European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28:2375-2414.
22. Herceptin (trastuzumab) package insert. South San Francisco, CA: Genentech; March 2009.
23. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
25. Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community:Astudy of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282-2289.
26. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952-4960.
27. Procter M, Suter TM, de Azambuja E et al. Longerterm assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:3422-3428.
28. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859-3865.
29. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
30. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5:63-69.
31. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
32. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment J Clin Oncol 2005;23:7820-7826.
33. Ewer MS, Lippman SM. Type II chemotherapyrelated cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 2005;23:2900-2902.
34. Hunt SA, Abraham WT, Chin MH et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
35. Bovelli D, Plataniotis G, Roila F, on behalf of the ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(Suppl 5):v277-v282.